Campbell Bradley L's Form 4 filing
Amicus Therapeutics, Inc. (FOLD) · filed Mar 3, 2023
- Accession no.
- 0001209191-23-015832
- Filed
- Mar 3, 2023
- Trade date
- Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $264.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Campbell Bradley LCIK 0001400971 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | Common Stock | MOption exerciseAcquired | +11,700 | $2.45 | +$28,665 | 856,829 | Direct | |
| Mar 1, 2023 | Common Stock | SSaleDisposed | −15,456 | $13.12F2 | −$202,782.72 | 841,373 | Direct | |
| Mar 1, 2023 | Common Stock | SSaleDisposed | −4,544 | $13.68F3 | −$62,161.92 | 836,829 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | Common Stock | MOption exerciseDisposed | −11,700 | $0.00 | $0 | 30,525 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.62 to $13.61 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.62 to $13.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.